It was reported to boston scientific corporation that an obtryx ii sling was implanted into the patient on (b)(6) 2016.The patient experienced complications, further surgery, and nonsurgical treatment.Patient symptoms include: eep (erosion/extrusion/protrusion of the mesh); back pain; vaginal pain; pelvic pain; groin pain; perineum pain; anal pain; rectal pain; thigh pain; other pain: like getting stabbed with a hot poker in abdomen & thighs; painful intercourse; inability to have intercourse; offensive vaginal discharge; difficulties with bowel motions; incontinence not present before implant; recurrent incontinence; aggravated incontinence; damage; psychiatric injury.Surgical interventions: - on (b)(6) 2019 the patient underwent further surgery regarding the obtryx ii implant under general anesthesia for the following purpose: cystoscopy, laparoscopy & bilateral salpingectomy.- on (b)(6) 2021 the patient underwent further surgery regarding the obtryx ii implant under general anesthesia for the following purpose: excision of vaginal mesh, cystoscopy & eua.- on (b)(6) 2021 the patient underwent further surgery regarding the obtryx ii implant under general anesthesia for the following purpose: excision of vaginal mesh & cystoscopy.Nonsurgical treatments: - on (b)(6) 2016 the patient commenced pain medication: ovestin cream, anpec for cluster headaches due to stress, vesicare, escitalopram for anxiety, neo mercazole for overactive thyroid.For the treatment of: infections, cluster headaches, anxiety, incontinence, overactive thyroid.Treatment duration: 5.- on (b)(6) 2018 the patient commenced incontinence medication: vesicare 5mg for the treatment of: for incontinence.Treatment duration: 4.- the patient was treated with psychological medication.On (b)(6) 2017 the patient commenced other medication (please specify): escitalopram 20mg for the treatment of: anxiety & depression.Treatment duration: 4.- on (b)(6) 2019 the patient commenced topical treatment (including oestrogen cream): ovestin for the treatment of: continual disgusting discharge & to help with repair before & after surgeries.Treatment duration: 3.- the patient was treated with other (not specified).- on (b)(6) 2017 the patient commenced pain medication: panadin forte for the treatment of: abdominal pain & cluster headaches.Treatment duration: 4.
|
(b)(6) the complainant was unable to provide the suspect device upn and lot number; therefore, the lot expiration and device manufacture dates are unknown.The upn provided was chosen as a representative upn to capture the implanted device.The complainant indicated that the device is not available for return; therefore, a failure analysis of the complaint device could not be completed.If any further relevant information is identified, a supplemental medwatch will be filed.
|